These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 19530681

  • 1. Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
    Liu W, Liu K, Wood HB, McCann ME, Doebber TW, Chang CH, Akiyama TE, Einstein M, Berger JP, Meinke PT.
    J Med Chem; 2009 Jul 23; 52(14):4443-53. PubMed ID: 19530681
    [Abstract] [Full Text] [Related]

  • 2. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
    Liu K, Xu L, Berger JP, Macnaul KL, Zhou G, Doebber TW, Forrest MJ, Moller DE, Jones AB.
    J Med Chem; 2005 Apr 07; 48(7):2262-5. PubMed ID: 15801817
    [Abstract] [Full Text] [Related]

  • 4. Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.
    Acton JJ, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, Einstein M, Liu K, McCann ME, Moller DE, Muise ES, Tan Y, Thompson JR, Wong KK, Wu M, Xu L, Meinke PT, Berger JP, Wood HB.
    J Med Chem; 2009 Jul 09; 52(13):3846-54. PubMed ID: 19507861
    [Abstract] [Full Text] [Related]

  • 5. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 09; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

  • 6. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C, Fruchart JC, Staels B.
    Curr Opin Pharmacol; 2006 Dec 09; 6(6):606-14. PubMed ID: 16973418
    [Abstract] [Full Text] [Related]

  • 7. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY.
    Eur J Pharmacol; 2008 Oct 24; 595(1-3):119-25. PubMed ID: 18727927
    [Abstract] [Full Text] [Related]

  • 8. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S, Matter H, Schönafinger K, Glien M, Mathieu M, Marquette JP, Michot N, Haag-Diergarten S, Urmann M, Wendler W.
    ChemMedChem; 2011 Apr 04; 6(4):633-53. PubMed ID: 21400663
    [Abstract] [Full Text] [Related]

  • 9. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
    Xu Y, Etgen GJ, Broderick CL, Canada E, Gonzalez I, Lamar J, Montrose-Rafizadeh C, Oldham BA, Osborne JJ, Xie C, Shi Q, Winneroski LL, York J, Yumibe N, Zink R, Mantlo N.
    J Med Chem; 2006 Sep 21; 49(19):5649-52. PubMed ID: 16970391
    [Abstract] [Full Text] [Related]

  • 10. Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.
    Le Naour M, Leclerc V, Farce A, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Lonchampt M, Dacquet C, Ktorza A, Berthelot P, Lebegue N.
    ChemMedChem; 2012 Dec 21; 7(12):2179-93. PubMed ID: 23047286
    [Abstract] [Full Text] [Related]

  • 11. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.
    J Med Chem; 2011 Dec 22; 54(24):8541-54. PubMed ID: 22070604
    [Abstract] [Full Text] [Related]

  • 12. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J, Chen L, Majumdar D, Bullock WH, Burns M, Claus T, Dela Cruz FE, Daly M, Ehrgott FJ, Johnson JS, Livingston JN, Schoenleber RW, Shapiro J, Yang L, Tsutsumi M, Ma X.
    J Med Chem; 2007 Mar 08; 50(5):984-1000. PubMed ID: 17274610
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.
    Shi Q, Canada EJ, Xu Y, Warshawsky AM, Etgen GJ, Broderick CL, Clutinger CK, Irwin LA, Laurila ME, Montrose-Rafizadeh C, Oldham BA, Wang M, Winneroski LL, Xie C, York JS, Yumibe NP, Zink RW, Mantlo N.
    Bioorg Med Chem Lett; 2007 Dec 15; 17(24):6744-9. PubMed ID: 18029178
    [Abstract] [Full Text] [Related]

  • 15. INT-131, a PPARgamma agonist for the treatment of type 2 diabetes.
    Kintscher U, Goebel M.
    Curr Opin Investig Drugs; 2009 Apr 15; 10(4):381-7. PubMed ID: 19337960
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
    Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, Yang M, Cryan E, Rybczynski P, Demarest K.
    Metabolism; 2008 Nov 15; 57(11):1516-25. PubMed ID: 18940388
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
    Grether U, Bénardeau A, Benz J, Binggeli A, Blum D, Hilpert H, Kuhn B, Märki HP, Meyer M, Mohr P, Püntener K, Raab S, Ruf A, Schlatter D.
    ChemMedChem; 2009 Jun 15; 4(6):951-6. PubMed ID: 19326383
    [Abstract] [Full Text] [Related]

  • 20. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes.
    Magae J, Tsuruga M, Maruyama A, Furukawa C, Kojima S, Shimizu H, Ando K.
    J Antibiot (Tokyo); 2009 Jul 15; 62(7):365-9. PubMed ID: 19557028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.